Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?

פריטים דומים

• Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non‐small‐cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
  מאת: Li, Xin, et al.
  יצא לאור: (2018)
• The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
  מאת: Rachiglio, Anna Maria, et al.
  יצא לאור: (2019)
• Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
  מאת: Offin, Michael, et al.
  יצא לאור: (2018)
• <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
  מאת: Xavier Cansouline, et al.
  יצא לאור: (2022-04-01)
• Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
  מאת: Takeda, Yuichiro, et al.
  יצא לאור: (2020)